Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold (Paid Option) |
|
as soon as is submitted to ZB.
Effects of finerenone in persons with CKD and T2D are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
Diabetes Obes. Metab. 25, 1512-1522 (2023)
AIMS: Effects of glycated hemoglobin (HbA1c), HbA1c variability, diabetes duration and insulin use on cardiorenal outcomes and diabetes progression in chronic kidney disease (CKD) and type 2 diabetes (T2D) are poorly understood. This post-hoc analysis of the prespecified, pooled FIDELITY dataset investigated the efficacy and safety of finerenone by these factors. MATERIALS AND METHODS: Composite efficacy outcomes included cardiovascular (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for heart failure), kidney (kidney failure, sustained ≥57% estimated glomerular filtration rate decline or renal death) and diabetes progression (new insulin initiation, increase in antidiabetic medication, 1.0% increase in HbA1c from baseline, new diabetic ketoacidosis diagnosis or uncontrolled diabetes). RESULTS: In 13,026 participants, risk reductions in the cardiovascular and kidney composite outcomes with finerenone vs placebo were consistent across HbA1c quartiles (P-interaction 0.52 and 0.09, respectively), HbA1c variability (P-interaction 0.48 and 0.10), diabetes duration (P-interaction 0.12 and 0.75) and insulin use (P-interaction 0.16 and 0.52). HbA1c variability in the first year of treatment was associated with higher risk of cardiovascular and kidney events (hazard ratio [HR] 1.20; 95% confidence interval [CI] 1.07-1.35; P = 0.0016 and HR 1.36; 95% CI 1.21-1.52; P < 0.0001, respectively). There was no effect on diabetes progression with finerenone or placebo (HR 1.00; 95% CI 0.95-1.04). Finerenone was well-tolerated across subgroups; discontinuation and hospitalization due to hyperkalemia were low. CONCLUSIONS: Finerenone efficacy was not modified by baseline HbA1c, HbA1c variability, diabetes duration or baseline insulin use. Greater HbA1c variability appeared to be associated with increased risk of cardiorenal outcomes. This article is protected by copyright. All rights reserved.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Cardiovascular Disease ; Clinical Trial ; Diabetes Complications ; Diabetic Nephropathy ; Type 2 Diabetes; Term Glycemic Variability; Cardiovascular Events; Risk; Outcomes; Heart; Complications; Nephropathy; Association; Dysfunction; Progression
ISSN (print) / ISBN
1462-8902
e-ISSN
1463-1326
Journal
Diabetes, Obesity and Metabolism
Quellenangaben
Volume: 25,
Issue: 6,
Pages: 1512-1522
Publisher
Wiley
Publishing Place
111 River St, Hoboken 07030-5774, Nj Usa
Non-patent literature
Publications
Reviewing status
Peer reviewed
Grants
Bayer AG